What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read Pharma Industry News Denifanstat phase 3 acne trial success positions Ascletis for China NDA submission in 2026 Find out how Denifanstat’s Phase 3 acne trial success positions Ascletis Pharma for a 2026 China NDA submission and reshapes the acne-therapy market. bySoujanya RaviOctober 24, 2025